Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million. bit.ly/40St7uG

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®. ow.ly/kbta50UTrsk

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook. ow.ly/OPCr50V1KbK

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®. ow.ly/I8Rc50V8jQ8

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences. ow.ly/47OL50V8wMY

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook. ow.ly/gr2b50Vl4OO

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion. ow.ly/o0ya50VmIMP

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F. ow.ly/wFkh50VnSBx

We're excited to launch our Annual Business Report website! The website provides insight into Valneva’s mission, financial outlook and serves as a hub for our 2024 annual results resources. To find out more, visit: ow.ly/Kik250VnAZK #AdvancingVaccinesForBetterLives

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA. ow.ly/Qsw350VqEix

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and above. ow.ly/j88f50VspEn

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2. ow.ly/iuBT50VwM4n

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country. ow.ly/IROL50VA0jB

Join us at World Vaccine Congress 2025! We are delighted that three members of the Valneva team will be sharing their knowledge at various events over the next few days. You can also visit us at booth #424. Read our press release here: ow.ly/ZOFW50VFiyO #WVCUSA

Today at the World Vaccine Congress, our Chief Scientific Officer, Dr Hanneke Schuitemaker will be leading a working group focused on on Prophylactic Enteric Disease Vaccines. You can also find our team at booth #424 - we hope to see you there! #WVCUSA

Today at the World Vaccine Congress our VP of Clinical Development, Susanne Eder-Lingelbach will be sharing vital insights into our chikungunya vaccine. Find us in Room 202B for her presentation. #WVCUSA

It’s the last day of the World Vaccine Congress. Don’t miss our Chief Medical Officer, Juan Carlos Jaramillo’s panel discussion addressing the importance of vaccines against mosquito borne diseases. You can also visit us at booth #424 to learn more about our work! #WVCUSA

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates. ow.ly/qbWm50VO615

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update. ow.ly/SLlb50W3Qy3

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®. ow.ly/5ulz50W4XpZ